Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (ND...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Federal Register
- Region
- USA
- Scope
- Regulatory
- Published
- June 22, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (ND...
Source route
Continue on federalregister.gov
Leave the platform to read the original full article on the publisher site.
Source: Federal Register
Scope: Regulatory
Related coverage
More related coverage
Drug label update: unspecified product
Official structured record identifier: 52cef8ec-6578-5e80-e063-6294a90ab423.
DHSC spending over £500
This series brings together all documents relating to Department of Health and Social Care (DHSC) sp...
DHSC: spending over £500, May 2026
Department of Health and Social Care spending by electronic purchasing card solution (ePCS), over £5...